Kancera Q1: Continued efforts with Recardio - Redeye
Redeye returns following Kancera's Q1 report. The investment case is currently centred around the letter of intent with Recardio Inc. Given the uncertainty surrounding the outcome, we continue to value the share based on our DCF model.
ANNONS
Redeye returns following Kancera's Q1 report. The investment case is currently centred around the letter of intent with Recardio Inc. Given the uncertainty surrounding the outcome, we continue to value the share based on our DCF model.